Robert Iannone - 03 Mar 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
EVP, Global Head of R&D and Ch
Signature
By: /s/Adam Guttmann, as attorney in fact For: Robert Iannone
Issuer symbol
JAZZ
Transactions as of
03 Mar 2022
Net transactions value
-$204,305
Form type
4
Filing time
09 Mar 2022, 16:54:45 UTC
Previous filing
22 Jun 2021
Next filing
08 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +11,374 +39% $0.000000 40,584 03 Mar 2022 Direct F1, F2
transaction JAZZ Ordinary Shares Tax liability $204,305 -1,327 -3.3% $153.96 39,257 05 Mar 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F2 Includes 124 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021.
F3 Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.